Fig. 2.
Effect of alirocumab, atorvastatin, and their combination on hepatic LDLR protein levels. * P < 0.05, ** P < 0.01 as compared with control; † P < 0.05, †† P < 0.01 as compared with atorvastatin (n = 8 per group).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.